The first and only combination of basal and prandial insulin analogs degludec and aspart: the position of Russian endocrinologists
Insulin therapy for diabetes mellitus is the most effective way to control glycemia with the progression of the disease and the ineffectiveness of other sugar-lowering drugs. At the same time, the existing limitations of traditional insulin preparations, along with increasing attention to the indivi...
Guardado en:
Autores principales: | M. V. Shestakova, E. V. Surkova, A. A. Vachugova, I. A. Ipatko, E. E. Kazakova, I. A. Karpova, M. A. Kovarenko, L. P. Kolimbet, E. E. Krasilnikova, M. N. Kuzin, E. Y. Pashkova, M. I. Kharakhulakh, O. G. Tsygankova |
---|---|
Formato: | article |
Lenguaje: | EN RU |
Publicado: |
Endocrinology Research Centre
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/baa29262204b47a191b0fad5c1e332e6 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Insulin degludec/insulin aspart is the first co-formulation of basal and prandial insulin analogues
por: Ivan Ivanovich Dedov, et al.
Publicado: (2014) -
Data on the first experience of insulin degludec (Tresiba®) treatment for type 2 diabetes in daily clinical practice
por: Lyudmila Alexandrovna Suplotova, et al.
Publicado: (2015) -
National advisory board on diabetes mellitus: unsolved issues and new opportunities for diabetes treatment
por: Gagik Radikovich Galstyan
Publicado: (2014) -
Insulin degludec: a new basal insulin analogue with an ultra-long duration of action. Safety and efficacy in Russian patients with diabetes
por: Marina Vladimirovna Shestakova, et al.
Publicado: (2015) -
Insulin degludec is a new ultra-long-acting insulin analogue
por: Ivan Ivanovich Dedov, et al.
Publicado: (2014)